Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Go back to Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 10.18 +0.81 (8.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.37 | 52 Week High | $9.23 | |||
| Open | $9.20 | 52 Week Low | $1.16 | |||
| Day High | $10.20 | P/E | N/A | |||
| Day Low | $9.19 | EPS | $-0.30 | |||
| Volume | 4,116,674 | |||||
